

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015, Fax : 0731-2723017
Tel : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel : 0731-2426700, 2426716, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
--	--

Date: 14/02/2020

Sub: - Outcome of the Board Meeting and Submission of Un-Audited Financial Results for the quarter and nine month ended 31st December, 2019 in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation, 2015.

Ref: Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014

This is in continuation of our letter dated 4th February 2020, regarding information for Board Meeting for consideration and approval of Un-audited Financial Results for the quarter as well as nine months ended 31st December, 2019.

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we are enclosing Un-audited Financial Results along with Limited Review Report for the quarter as well as nine months ended 31st December, 2019 duly approved by the Board of the Directors of the Company in their meeting held today i.e. on 14th Day of February, 2020.

Further, copy of Un-Audited Financial Statements and Limited Review Report shall also be submitted in XBRL mode (Excel Template provided by Exchange) within 24 hours from the conclusion of Board Meeting.

The aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper. These results shall also be uploaded on the website of the Company i.e. www.biofilgroup.net and on the website of the Stock Exchanges at www.bseindia.com and www.nseindia.com.

Further Board has also accorded their permission to merge Plastic Division to Chemicals Division, in respect of which disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, shall be given separately within prescribed time.


The Meeting of the Board of Directors commenced at 7:00 pm and concluded at 8:30 p.m.

Kindly take above said financial result for your reference and record.

Thanking You,

Yours faithfully

For Biofil Chemicals and Pharmaceuticals Limited


For-Biofil Chemicals & Pharmaceuticals

Ramesh Shah
Managing Director
DIN: 00028819

Managing Director


Enclosure:- Un-Audited Financial Results for the quarter and nine month ended 31st December, 2019.

Biofil Chemicals and Pharmaceuticals Limited
 Reg. office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)
 CIN L24233MP1985PLC002709

Email Id: bcplcompliance@gmail.com website: www.biofilgroup.net
 Phone No. 0731-2426718, 2723016-17

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st December, 2019

Particulars	Quarter Ended			Nine Month Ended		Audited for the year ended March 31 2019
	3 months ended (31/12/2019)	Preceding 3 months ended (30/09/2019)	Corresponding 3 months ended in the previous year (31/12/2018)	Year to date figures for current period ended (31/12/2019)	Year to date figures for the previous year ended (31/12/2018)	
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	
I Revenue from Operation						
II Other Income	1275.20	1162.88	1429.402	2597.50	636.01	2312.85
III Total Revenue (I+II)	8.86	3.36	2.017	13.33	3.66	10.12
	1284.06	1166.24	1431.42	2610.83	639.67	2322.98
IV Expenses						
(a) Cost of materials consumed						
(b) Purchases of stock-in-trade	83.75	97.60	31.133	268.02	32.81	77.27
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	11.20	2119.94	557.368	2156.17	1277.63	1904.95
(d) Employee benefits expense	1,096.81	(1,205.14)	758.010	(122.28)	(798.14)	17.04
(e) Finance Cost	32.50	21.46	20.907	72.93	41.39	89.22
(f) Depreciation and Amortisation Expense	2.87	3.27	3.880	9.73	7.79	16.03
(g) Other expenses	9.45	9.45	7.440	28.03	14.60	36.51
Total expenses (IV)	24.56	40.53	23.367	92.27	46.72	122.12
V Profit (Loss) before exceptional items and tax (III-IV)	1261.12	1087.11	1402.10	2504.87	622.79	2263.15
VI Exceptional Items	22.94	79.13	29.31	105.96	16.88	59.83
VII Profit (Loss) before tax (V - VI)	0.00	0.00	0.00	0.00	0.00	0.00
VIII Tax expense:	22.94	79.13	29.31	105.96	16.88	59.83
(1) Current tax						
(2) Deferred tax Credit/(Charge)	0.00	0.00	0.00	0.00	0.00	11.60
IX Profit (Loss) for the period from continuing operation VII-VIII	0.00	0.00	0.00	0.00	0.00	0.00
X Profit (Loss) for the period for dis-continued operation	22.94	79.13	29.31	105.96	16.88	48.23
XI Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00	0.00
XII Profit/(loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII Profit (Loss) for the period (IX+XII)	0.00	0.00	0.00	0.00	0.00	0.00
XIV Other Comprehensive Income	22.94	79.13	29.31	105.96	16.88	48.23
A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
B) (i) Items that will be reclassified to Profit or Loss						
(II) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
XV Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	22.94	79.13	29.31	105.96	16.88	48.23
XVI Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
XVII Reserves (Excluding Revaluation Reserve)						(638.63)
XVIII Earnings per equity shares (for continuing operation):						
(1) Basic (Rs)						
(2) Diluted (Rs)	0.14	0.49	0.18	0.65	0.10	0.30
	0.14	0.49	0.18	0.65	0.10	0.30


Biofil Chemicals & Pharmaceuticals Ltd

 Managing Director

1. The above unaudited results for the Quarter and nine month ended December 31, 2019 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 14th February, 2020. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
2. The Company has reported segment wise information as per Accounting Standard (AS-17). The Operations of the company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
 - I. Pharma Product
 - II. Chemicals Division
3. Plastic division did not carried out business activities during the last nine quarters, commencing from 1 st July 2017 and ending on 30th September 2019 resultant to which the division has minimum bearing expenses against zero income, which leads to the loss in plastic division further it would be feasible if said plastic division be merged to Chemical Division of the Company for smooth function and working of the Company as plastic division and Chemical Division are part of same unit i.e. Pithampur unit of the Company. Further there is no implication on financial position of the Company if both the division are merged.
4. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
5. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
6. The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors.
7. The Company has adopted IND AS 116 "Leases" effective from 01.04.2019 and applied standard to its Leases.

Date : 14-Feb-2020

Place Indore

FOR Biofil Chemicals & Pharmaceuticals Limited



RAMESH SHAH
MANAGING DIRECTOR
(DIN : 00028819)

Biofil Chemicals and Pharmaceuticals Limited
 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)
 CIN L24233MP1985PLC002709
 Email bd:bcplcompliance@gmail.com website:- www.biofilgroup.net
 Phone No. 0731-2426718, 2723016-17

Segmentwise Revenue, Results and Capital Employed for the quarter ended 31st Dec 2019

S.No.	Segment Revenue	(Amount in Lakhs)					
		Quarter Ended			Nine Month Ended		
		Dec 31 , 2019	Sept 30 , 2019	Dec 31 , 2018	Dec 31 , 2019	Dec 31 , 2018	31 March 2019
1	Segment Revenue	Reviewed	Reviewed	Reviewed	Reviewed	Reviewed	Audited
		30.09.2019	30-09-2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019
	Pharma Unit	1,148.23	998.46	1,379.950	2,202.28	998.462	2,110.13
	Chemicals Division	126.97	164.42	49.452	395.22	164.421	202.73
	Plastic Division	0.00	0.00	0.000	0.00	0.000	0.00
	Other	7.29	2.32	2.017	10.72	2.320	7.98
	Gross Turnover	1,282.49	1,165.20	1,431.42	2,608.22	1,165.20	2,320.84
2	Segment Results						
	Pharma Unit	22.47	67.82	18.190	98.35	67.822	63.52
	Chemicals Division	1.77	14.57	15.004	19.30	14.575	22.36
	Plastic Division		(1.06)	0.000	(4.63)	(1.063)	(3.69)
	Other				0.00	0.00	(8.45)
	Total Segment Profit Before Tax	24.24	81.33	33.19	113.02	81.33	73.72
	Interest Income	1.57	1.04		2.61	1.039	2.14
	Interest Expenses	2.86	3.25	3.880	9.67	3.246	16.03
	Other Unallocable Income net of Expenditure						
	Profit Before Tax	22.94	79.13	29.31	105.96	79.13	59.83
	Provision for current tax	0.00	0.00	0.00	3.00	0.00	11.51
	Item Related Earlier Year	0.00	0.00	0.00	0.00	0.00	0.09
	Profit After Tax	22.94	79.13	29.31	105.96	79.13	48.23
3	Capital Employed						
	Segment Assets (A)						
	Pharma Division	3,440.20	3,424.07	2,378.705	3,440.20	2,378.705	1,411.32
	Chemicals Division	1,170.88	1,073.39	914.368	1,170.88	914.368	958.88
	Plastic Division	0.00	51.11	60.450	0.00	60.450	51.11
	Other						
	Total (A)	4,611.08	4,548.57	3,353.52	4,611.08	3,353.52	2,421.30
	Segment Liabilities (B)						
	Pharma Division	2,753.52	2,762.38	1,815.785	2,753.52	1,815.785	792.75
	Chemicals Division	337.43	175.91	35.651	337.43	35.651	98.00
	Plastic Division	0.00	143.71	169.521	0.00	169.521	165.58
	Other				0.00	0.00	
	Total (B)	3,090.95	3,082.00	2,020.96	3,090.95	2,020.96	1,056.33
	Total Capital Employed (Segment Assets- Segment Liabilities)						
	Pharma Division	686.67	661.69	562.92	686.67	562.92	618.56
	Chemicals Division	833.45	897.48	878.72	833.45	878.72	860.88
	Plastic Division	0.00	(92.60)	(109.07)	0.00	(109.07)	(114.48)
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets- Segment Liabilities)	1,520.12	1,466.57	1,332.57	1,520.12	1,332.57	1,364.97

Plastic division did not carried out business activities during the last nine quarters, commencing from 1 st July 2017 and ending on 30th September 2019 resultant to which the division has minimum bearing expenses against zero income, which leads to the loss in plastic division further it would be feasible if said plastic division be merged to Chemical Division of the Company for smooth function and working of the Company as plastic division and Chemical Division are part of same unit i.e. Pithampur unit of the Company. Further there is no implication on financial position of the Company if both the division are merged. For the purpose of comparison, Plastic Division figures has been shown separately.

DATE : 14-02-2020
 PLACE: INDORE

FOR Biofil Chemicals & Pharmaceuticals Limited

Ramesh Shah
RAMESH SHAH
 MANAGING DIRECTOR
 (DIN: 00028819)



Review report to **Biofil Chemicals and Pharmaceuticals Limited**


We have reviewed the accompanying statement of unaudited financial results of **Biofil Chemicals and Pharmaceuticals Limited** for the period ended **31st December 2019**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For **MAHESHWARI & GUPTA**
Chartered Accountants
FRN:006179C



CA. SUNIL MAHESHWARI
Partner
M.No.: 403346

PLACE : **INDORE**
DATE : 14/02/2020